The Day In Review: Bristol-Myers Squibb Company Releases Drug News

November 14, 2005 -- Bristol-Myers Squibb dominated the news about drug tests today, releasing data from trials involving a number of different drugs. On the plus side, the oral antiviral agent Baraclude was found to be effective against hepatitis B; but Plavix did not prevent strokes among patients with irregular heart rhythms; nor did edifoligide prevent veins from clogging during coronary bypass surgery; Abbott Labs reported that Tricor, a cardiovascular drug, did not lower the incidence of heart attacks or death among diabetes patients; Merck won approval for an added indication for its antibiotic Invanz; Avant Immunotherapeutics climbed significantly higher after saying it would develop a mass-scale bird flu vaccine; and OSI Pharma closed its purchase of Eyetech today, despite its apparent misgivings about Macugen. The Centient Biotech 200™ ended the trading session today virtually flat, moving just a half-point lower to 3933.62, a .01% loss. More details...

MORE ON THIS TOPIC